In both cohorts, GBM patients with higher PD-L1 expression had shorter overall survival (Figure 1C TCGA, median survival: PD-L1high vs PD-L1low, 375 vs 453 days, p = 0.0272; Figure 1D CGGA, median survival: PD-L1high vs PD-L1low, 315 vs 567 days, p = 0.0021). This evidence concerns the gene CD274 and glioblastoma.